INTRODUCTION {#s1}
============

Whole-breast external beam radiotherapy (EBRT) following breast-conserving surgery (BCS) has equivalent overall survival and local recurrence rates (LRR) compared with total mastectomy \[[@R1]--[@R3]\], and has the advantage of preserving the breast. The LRR after BCS and conventional radiotherapy (RT) is typically less than 1% per year, and ranges between 4--7% at 5 years \[[@R4], [@R5]\]. A further reduction in LRR of up to 40% can be achieved by an additional external radiation boost of 10--16 Gy to the tumor bed \[[@R6]\]. However, in many countries, up to 30% patients who undergo BCS for early breast cancer decline RT or even opt for mastectomy to avoid radiotherapy because they live a substantial distance from a RT center, or have significant co-morbidities, or difficulties that prevent them from attending daily treatment, especially true for older women \[[@R7], [@R8]\]. In addition, the increasing use of oncoplastic breast surgery which often rearranges the tumor bed position, amplifies the challenge of accurate delivery of RT boost to the tumor bed, even when the surgeon routinely places cavity clips to help in targeting the tumor bed \[[@R9], [@R10]\].

However, 5 to 7 weeks of RT after BCS, which is both inconvenient and costly to patients, might not always be needed. Schnitt et al. \[[@R11]\] and Veronesi et al. \[[@R12]\] indicate that the vast majority of recurrences after BCS occur in the index quadrant. It has been observed that up to 90% of local recurrences are at or near the original operation site \[[@R13]--[@R15]\], and the LRR in other quadrants was approximately 15%, approaching the risk of contralateral breast cancer \[[@R6]\]. This observation, and the desire to increase the acceptance of RT after BCS, has led to an interest in Accelerated Partial Breast Irradiation (APBI) techniques that focus radiation specifically on the index quadrant. Intraoperative radiotherapy (IORT) is one technique for delivering APBI. IORT delivers the radiation at the time of surgery, thus accurately defining the target volume of the breast and specifically targeting the tumor cavity.

Because IORT is delivered in a single fraction during surgery with the surgeon directly visualizing the target, it enables maximum precision in the delivery of the dose and reduces the dose to healthy surrounding tissues \[[@R16]\]. Compared with whole breast radiotherapy, it has the following advantages: 1) accurate positioning of radiation field, high surface dose, and uniform target dose; 2) single high-dose radiation potentially avoids residual tumor cell repair and proliferation that can occur due to delay in delivering fractionated radiotherapy, thereby improving the biological effect; 3) avoids dose to vital organs (heart, lungs, etc.); 4) less dose to normal tissues, reducing the risk of radiation-induced second primary tumors; 5) shortened overall treatment time; 6) better cosmetic outcome with less pigmentation, dryness and swelling of skin; 7) reduction in healthcare costs. The disadvantages of IORT are: 1) increased operating times; 2) lack of final pathological results before delivering IORT; 3) small increase local recurrence rates compared with conventional EBRT in two RCTs \[[@R17], [@R18]\]; 4) staff training and operating room equipment efforts; 5) expensive devices \[[@R19]\].

While IORT has been studied by a large number of clinical trials in America and Europe, the clinical efficacy and cosmetic outcome of IORT in Chinese Han population or even Asian people, still lack evidence. In our study, we enrolled 50 Chinese Han early breast cancer patients to receive breast-conserving surgery and IORT using a mobile electron accelerator (Mobetron 1000, IntraOp, Sunnyvale, CA). Postoperative recurrences, metastases, complications and cosmetic outcome were followed up to evaluate the safety and feasibility of IORT after BCS.

MATERIALS AND METHODS {#s2}
=====================

Patients {#s2_1}
--------

Chinese Han patients with early breast cancer who were eligible for BCS were offered participation in an IORT study at the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, China using a mobile electron accelerator (Mobetron^®^, Intraop Medical, Sunnyvale, CA, USA).

Preoperative mammography, ultrasound and MRI were used to exclude multifocal cancer, and preoperative imaging and clinical examination was used to exclude any obvious axillary lymph node involvement. Patients found on postoperative pathological examination to have more than 3 axillary lymph node metastases were eliminated from the study and treated with modified radical mastectomy and postoperative radiotherapy. This study was conducted with approval from the Ethics Committee of the Cancer Hospital Chinese Academy of Medical Sciences and in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.

From July 2008 to Dec 2012, 50 patients were entered into the study. Fourteen patients (28%) had IORT as a boost followed by 5 weeks of WBI, while 36 patients (72%) had IORT as their sole radiation treatment. The median age of the patients was 46.9 years (range 26--70 years). All tumors were ≤ 3 cm in size without invasion of the skin, adjacent muscles or chest wall. The detailed clinical data of patients is summarized in Table [1](#T1){ref-type="table"}.

###### Patient characteristics (*n* = 50)

  Characteristics                                        IORT boost   IORT only   Total number   Percentage of total (%)
  ------------------------------------------------------ ------------ ----------- -------------- -------------------------
  Patient Treatment                                      14           36          50             100
  Age (years) ≤35                                         2            4           6              12
   36--55                                                11           23          34              68
   ≥56                                                    1            9          10              20
  Tumor position                                                                                 
   upper outer quadrant                                  11           20          31              62
   lower outer quadrant                                   1            5           6              12
   upper inter quadrant                                   2           10          12              24
   lower inter quadrant                                   0            1           1              2
  Tumor maximum diameter                                                                         
   ≤2cm                                                  11           29          40              80
   \>2cm                                                  3            7          10              20
  Histological Examination                                                                       
   Ductal carcinoma *in situ*                             1            3           4              8
   Invasive ductal carcinoma                             13           30          43              86
   Mucinous adenocarcinoma                                0            2           2              4
   Intraductal papillary carcinoma                        0            1           1              2
  Lymph node metastasis (pathology)                                                              
   NO                                                     9           33          42              84
   N1                                                     5            3           8              16
  Immunohistochemistry                                                                           
   ER+/and/or/PR+                                         9           24          33              66
   ER- and PR-                                            5           12          17              34
   Her-2+                                                 6            3           9              18
   HER-2−                                                 8           33          41              82
   Chemotherapy                                           9           24          33              66
   Targeted therapy[\*](#tfn_001){ref-type="table-fn"}    1            3           4              8

Herceptin treatment for one year

Surgical operation {#s2_2}
------------------

Of the 50 patients, 27 underwent BCS and sentinel lymph node biopsy, 22 BCS and ipsilateral axillary lymph node dissection (ALND), and one was a resection of local recurrence after previous BCS. Technetium-99m was injected into four points along the side of the areola hypodermic 2 hours before surgery. A gamma detector was used to label sentinel lymph nodes. The axillary incision over the skin and subcutaneous tissue along the axillary fold was performed to remove and biopsy the radiolabeled sentinel lymph node. The ALND included clearing of level I and II lymph nodes in the Berg muscle-based categorization, which should be at least 10. Using a curved or radial incision, the skin and subcutaneous tissue were cut with the tumor at the center. The tumor and approximately 2 cm of adjacent normal breast tissue were resected and underwent frozen-section pathologic diagnosis to ensure the margins were clear. If the resection margins were positive, re-excision would be performed. Fortunately, there was no positive margin on final pathology in this study. A purse-string suture was applied to the gland around tumor bed and was tightly wrapped so that when the electron beam applicator was centered on the sutured gland, it would ensure homogeneity of the irradiated target. A 2 mm-thick lead disk was positioned under the breast gland to protect chest-wall and underlying ribs, lung and heart.

IORT Treatment {#s2_3}
--------------

IORT was delivered, either as a boost or APBI IORT treatment, using a mobile electron accelerator (Mobetron^®^, Intraop, USA). Prior to the surgery the Mobetron was placed in the operating room and disinfected. The radiation oncology team selected the proper electron beam energy and collimator diameter such that 90% of the prescribed dose would cover at least 1.5 cm of tissue adjacent to the margins and at least 1 cm of breast tissue on the chest wall surface. The energy of the electron beam ranged from 6 to 12 MeV and the prescription dose to the target area was 9 Gy (boost) or 20 Gy (APBI IORT) using single irradiation of 3--5 min duration.

Postoperative treatment {#s2_4}
-----------------------

All patients received post-operative adjuvant chemotherapy and/or endocrine therapy appropriate to their clinical staging and pathological findings. The 14 patients who received IORT as a boost, also received postoperative irradiation of 50 Gy to the whole breast (25 fractions × 2 Gy/fraction) using 6 MV x-rays. Postoperative radiation was delayed for 126 days (4 months) for those IORT boost patients requiring adjuvant chemotherapy.

Follow-up and cosmetic outcome evaluation {#s2_5}
-----------------------------------------

Patients were followed every 3-months from the surgery by either outpatient visits or by telephone. The primary outcomes of the study were local recurrence, metastases and mortality. Secondary outcomes included complications and cosmetic evaluation and quality of life. The cosmetic outcome was scored as excellent/good/fair/poor in accordance with the grading system developed by Harris et al. \[[@R20]\] The treated breast was compared with the untreated breast to score these items. Excellent meant there was no difference between breasts; Good meant there was only a slight difference; Fair was when a marked difference was present; and Poor was in case of a significant difference. The scores given for each patient by different reviewers were combined into a single average.

RESULTS {#s3}
=======

Follow-up {#s3_1}
---------

The median follow-up was 51.8 months (range 22.6 to 75.7 months). We observed 2 (4.0%) recurrences, occurring 12 months and 25 months after surgery. Both were single fraction patients, one DCIS and the other a Mucinous tumor. Both patients were salvaged by total mastectomy. No metastases or deaths occurred. The overall outcome and adverse events of the enrolled patients are shown in Table [2](#T2){ref-type="table"}.

###### Overall outcome of the enrolled patients (*n* = 50)

  Characteristics                                          Number   Percentage (%)
  -------------------------------------------------------- -------- ----------------
  primary outcomes                                                  
   Local recurrences                                       2         4
   Metastasis                                              None     
   Death                                                   None     
  Cosmetic outcome                                                  
   Excellent or good                                       44       88
   Fair or poor                                            6        12
  Wound healing (average wound healing time was 17 days)            
   Infection                                               3         6
   Healing delay                                           5        10
   Wound edema                                             2         4
   Fat deliquescence                                       None     
  Adverse events                                                    
   Skin pigmentation                                       3         6
   Ipsilateral breast infection                            None     
   Acute hematological toxicity                            None     
   Haematoma                                               None     

Wound healing {#s3_2}
-------------

The average wound healing time in study group was 17 days. Infection occurred in 3 patients (6.0%), healing delay in 5 patients (10.0%), and wound edema in 2 patients (4.0%). However, there was no fat deliquescence or hematomas.

Cosmetic evaluation of postoperative breast appearance {#s3_3}
------------------------------------------------------

Cosmetic outcome was evaluated after surgery at 1 year. 44 patients (88.0%) were graded as excellent or good, while 6 patients (12.0%) were rated as fair or poor.

Adverse events {#s3_4}
--------------

In this study, 3 patients (6.0%) showed mild skin pigmentation. There was no intraoperative or postoperative radiation-related acute hematological toxicity or other adverse reactions.

DISCUSSION {#s4}
==========

While BCS plus 5--7 weeks of RT in early stage breast cancer remains the standard treatment to preserve the breast in much of the world, both the Canadians \[[@R21]\] and the UK START-B studies \[[@R22]--[@R24]\] found that d 40 Gy in 15 fractions gave equivalent results. Consequently, 3 weeks of RT after BCS, with or without a boost, is rapidly becoming the standard treatment because the shortened treatment schedule is more convenient and less costly than the 5 week RT approach. In some countries, such as China, even 3--4 weeks of RT can be an obstacle for women living far from a radiation center or for older women who are less concerned with cosmesis. Our goal in this study, was to see if we could increase breast preservation in China by radically reducing the time for the required radiation. Veronesi et al. \[[@R25]\] and others \[[@R26]\] have estimated that a single fraction of 21 Gy is biologically equivalent the standard 5--7 weeks of RT.

Even though the recently published ELIOT trial \[[@R17]\] with mature follow-up of 5.7 years, resulted in a higher LRR than the EBRT group (4.4% vs. 0.4%), there importantly was no difference in survival even at 10 years. In addition, grade 3 or 4 skin complications were significantly reduced with IORT. It has been suggested that improved selection of patients might reduce the rate of local recurrence to \< 2% at 5 years \[[@R26], [@R27]\] with IORT.

In our study, despite a much younger patient population and other higher risk factors than published in other studies, there were just 2 cases (4.0%) of LRR, but no metastases or deaths. The cosmesis and toxicities were quite acceptable, with 44 patients (88.0%) graded as excellent or good, and only 3 patients (6.0%) with wound infection 5 patients (10.0%) with healing delay, and 2 patients (4.0%) with wound edema. No patient had fat deliquescence or hematomas. Furthermore, unlike another Asian study \[[@R26]\], we experienced no hypertrophic scarring. The average wound healing time in our study group was 17 days. Through longer follow-up is needed, no patients experienced radiation injury, which indicates the clinical safety of IORT and encourages us to continue to evaluate and refine this treatment technique with the aim of increasing breast preservation in China without jeopardizing patient survival.

CONCLUSION {#s5}
==========

For early-stage breast cancer patients, intraoperative radiotherapy after breast-conserving surgery in the Chinese Han population is both safe and reliable and has resulted in very acceptable cosmetic outcomes. IORT has the potential to greatly increase the breast preservation rate in China, though a longer follow-up will be needed to fully understand which patients can safely benefit from this treatment approach.
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